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Abstract
Background: Both standard and low-dose allergen provocations are an established tool in asthma research to
improve our understanding of the pathophysiological mechanism of allergic asthma. However, clinical symptoms
are less likely to be induced. Therefore, we designed a protocol for repetitive high-dose bronchial allergen
challenges to generate clinical symptoms and airway inflammation.
Methods: A total of 27 patients aged 18 to 40 years with positive skin-prick tests and mild asthma underwent
repetitive high-dose allergen challenges with household dust mites for four consecutive days. Pulmonary function
and exhaled NO were measured at every visit. Induced sputum was analysed before and after the allergen
challenges for cell counts, ECP, IL-5, INF-γ, IL-8, and the transcription factor Foxp3.
Results: We found a significant decrease in pulmonary function, an increased use of salbutamol and the
development of a late asthmatic response and bronchial hyperresponsiveness, as well as a significant induction of
eNO, eosinophils, and Th-2 cytokines. Repeated provocation was feasible in the majority of patients. Two subjects
had severe adverse events requiring prednisolone to cope with nocturnal asthma symptoms.
Conclusions: Repeated high-dose bronchial allergen challenges resulted in severe asthma symptoms and marked
Th-2-mediated allergic airway inflammation. The high-dose challenge model is suitable only in an attenuated form
in diseased volunteers for proof-of-concept studies and in clinical settings to reduce the risk of severe asthma
exacerbations.
Trial registration: ClinicalTrials.govNCT00677209
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Foxp3
Background
Bronchial allergen provocation models are well estab-
lished in asthma research and allow the evaluation of
antiallergic and antiasthmatic agents in relatively small
sample sizes [1,2]. Two different approaches to investi-
gate the action of a drug exist. The classical approach is
when subjects are challenged with an allergen before
and after treatment with antiallergic or antiasthmatic
drugs [3-6] and they are selected to develop a reprodu-
cible early and late asthmatic response (EAR and LAR)
as well as changes in sputum parameters. Usually
subjects do not develop subsequent asthma symptoms
or an increased medication use.
The other provocation model imitates the natural al-
lergen exposure. On consecutive days, a small amount
of an allergen is inhaled to induce bronchial inflamma-
tion. In previous studies that used this approach, the
subjects developed increased exhaled nitric oxide (eNO)
and increases in the levels of eosinophils and Th-2
derived cytokines [7-14]. However, repeated low-dose al-
lergen challenges did not provoke significant asthma
symptoms with changes in FEV1 and induction of an
LAR.
In a high-allergen provocation model provided by
Grainge and Howarth [15], three consecutive challenges
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four consecutive challenges in one week may be more
likely to induce symptoms and an allergen-driven
asthma exacerbation in diseased volunteers. Such a chal-
lenge model not only allows for the investigation of the
airway responses and inflammation, but it also provides
a strong indication of whether the clinical symptoms/
exacerbations can be reduced in proof-of-concept stud-
ies in small patient samples. Therefore, repeated high-
dose allergen challenges might combine both models,
specifically, the induction of asthma with obstruction of
the airways and significant changes in the forced expira-
tory volume in 1 second (FEV1) as well as the induction
of airway inflammation with changes of eNO, eosino-
phils, and cytokines in sputum.
In repeated challenges, safety concerns support an in-
cremental approach in which the allergen response can
be monitored between increasing doses [16]. However,
the single-step method may provide certain distinct
advantages, e.g., the ability to allow for the exact and
equivalent timing of allergen administration between
subjects. Moreover, in studies of the inflammatory re-
sponse, the single-step challenge may ensure that a con-
stant allergen dose is delivered at any given time [2].
New antiallergic drugs are emerging, and the high-
dose provocation model might be a tool to detect the
potency of the agent in a short period and in a small
sample size. We investigated volunteers who were aller-
gic to household dust mites using repeated high-dose al-
lergen provocations. In the provocation period, the use
of salbutamol, changes in FEV1, eNO, bronchial hyperre-
sponsiveness (BHR) and inflammatory cytokines in
induced sputum were investigated.
Methods
Subjects and selection
The present study was part of the study “Safety, toler-
ability, and impact on allergic inflammation of autolo-
gous E.coli autovaccine in the treatment of house dust
mite asthma - a prospective open clinical trial” [17]. Par-
ticipants were screened to have a positive skin-prick test
and a positive bronchial challenge against household
dust mites, as well as increases in eNO and in sputum
cells and cytokines. Twenty-seven subjects were invited
to undergo repeated high-dose allergen challenges. All
had mild asthma (GINA 1°) and subjects who used a
regular therapy with inhaled or oral corticosteroids,
long-acting beta-agonists, or leukotriene receptor
antagonists were excluded.
All participants supplied written informed consent
prior to the study. Human experimentation guidelines of
Good Clinical Practice, the German Drug Act and the
declaration of Helsinki/Hong Kong were followed in the
conduct of clinical research.
The study had been approved by the ethical committee
of the University of Frankfurt.
ClinicalTrials.govNCT00677209
Study design
Our cross-sectional study encompassed screening visits
and a challenge period with five consecutive visits (visits
1 – 5), eight months apart (Figure 1.). At the screening
visits, an initial bronchial challenge with incremental
doses of mite allergen was performed to define the dose
of allergen that caused a 15% drop in FEV1 from base-
line in the EAR (PD15FEV1 allergen). In all subjects the
PD15FEV1 allergen was re-challenged in single-step pro-
vocations on separate days to ensure that subjects met a
15%±5 drop in FEV1. If FEV1 was outside the expected
range, the dose was adjusted, and the subjects were re-
challenged until they met the objective of 15%±5.
After the screening visits the elected subjects started
with the autovaccine treatment. Another four weeks
after the intervention, the provocations were performed.
During the provocation period on the first visit (day 1)
all subjects underwent methacholine challenge testing
(MCT), induced sputum was collected, and a first, calcu-
lated, single-step dose of mite allergen (PD15FEV1)w a s
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Figure 1 Study design.
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single-step challenges with PD15FEV1 allergen were
repeated. On day 5 (visit 5) MCT and sputum collection
were repeated. At each visit, pulmonary function and
eNO were measured, a medication score was recorded,
and peak-flow was measured after each visit hourly for
at least ten hours to detect LAR. The LAR was defined
as a 15% drop in PEF 3–7 hours post-challenge; subjects
filled a protocol that was reviewed the next day.
All subjects were re-invited 18 months after visit 5 for
a long-term follow-up.
Pulmonary function test
Baseline pulmonary function tests were performed using
the MasterScreen spirometer (CareFusion, Germany).
The following parameters were recorded: forced vital
capacity (FVC), forced expiratory volume in one second
(FEV1), and Tiffeneau index (FEV1%FVC). For the FVC
and FEV1 manoeuvres, ATS/European Respiratory Soci-
ety test criteria for acceptability and repeatability [18]
should be met in all measurements.
Methacholine challenge testing
MCT was performed using the Aerosol Provocation Sys-
tem (APS, MedicAid-dosimeter, CareFusion, Germany).
The APS dosimeter technique (CareFusion, Germany)
allows computer-controlled production of aerosol using
a jet-type nebuliser (Sidestream, MedicAid) powered by
compressed air. The integrated pressure calibration pro-
cedure associated with the compressor ensures a highly
constant and reproducible nebuliser output. The APS
was calibrated to produce a continuous output of
240 mg/min. Several studies have shown particle size in
terms of mass median aerodynamic diameter of approxi-
mately 3.2 μm, and an average of the fine particle frac-
tion <5 μm of 49.7%.
MCT was performed, as described previously [19].
The doses of inhaled methacholine with a concentration
of 16 mg/mL were increased according to the following
pattern from step 1 to 5: 0.01, 0.1, 0.4, 0.8, and 1.6 mg.
Thus, the entire protocol delivered cumulative doses of
0.01, 0.11, 0.51, 1.31, and 2.91 mg. Two minutes after
each inhalation, spirometry was performed. The individ-
ual provocation dose (PD) causing a 20% drop in FEV1
(PD20FEV1) was calculated by logarithmic interpolation
using an integrated programme.
Specific allergen challenge
The Specific bronchial challenge with mite allergen was
performed using the APS dosimeter technique (CareFu-
sion Germany). Before each challenge, lyophilised mite
allergen (Allergopharma KG, Reinbek, Germany) was
resolved in 5 mL of 0.9% saline as a solution of 5000
SBU mL
-1 (standardised biological unit).
Incremental challenge
The incremental challenge protocol consistently fol-
lowed the same algorithm, as described previously [2].
The dose of inhaled allergen was doubled beginning with
the lowest dose of 10 SBU according to the following
pattern from step 1 to step 5: 10, 20, 40, 80, and 160
SBU. Therefore, the entire protocol delivered cumulative
doses of 10, 30, 70, 150, and 310 SBU. Ten minutes after
each step-up, FEV1 was measured. Inhalation was
stopped if FEV1 dropped≥15% compared to the baseline
values. The individual allergen dose that caused a 15%
drop in FEV1 in the EAR (PD15FEV1 allergen) was calcu-
lated using a logarithmic interpolation between the
doses before and after the 15% drop in FEV1 (Table 1).
Single-step challenge
The single-step challenge was performed, as described
previously [2]. Before each single-step challenge, the
APS was programmed to deliver the individual dose of
allergen that caused a 15% drop in FEV1 (PD15FEV1)b y
a technician or physician. At 10, 15, and 30 minutes
after each challenge, spirometry was performed to deter-
mine the maximum decrease in FEV1 (EAR) compared
to the initial values. A fall in FEV1 of 15% +/− 5w a s
accepted. If the drop was more than 20% or less than
10%, the single-step dose was adjusted according to the
deviation of FEV1 and re-challenging doses were admi-
nistered at least seven days apart. After the challenge
procedure, patients received two to four puffs of Salbu-
tamol (0.1 mg) until the FEV1 value returned to at least
90% of the baseline value. Peak flow was measured for
up to ten hours following the challenge, and a LAR was
defined as a drop of ≥15% PEF. Subjects received an ac-
tion plan and rescue medication consisting of salbutamol
and prednisolone.
Table 1 Subject’s characteristics
Total
Subjects [n] 27
Male/Female [n] 12/15
Age [yr, mean±SD] 24.8±4.0
FVC [%pred, mean±SD] 107.7±10.4
FEV1 [%pred, mean±SD] 103.4±12.7
FEV1%FVC [%, mean±SD] 79.9±8.2
Total IgE [kU/L, mean±SD] 165.9±130.6
Spec. IgE D.pter. [kU/L, mean±SD] 26.3±25.2
PD15FEV1 mite [SBU, mean±SD] 62.4±53.6
PD20FEV1 metha [mg, mean±SD] 1.3±1.1
eNO [ppB, mean±SD] 27.1±14.6
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Measurements of exhalative NO were collected using
the NIOX1 (Aerocrine, Solna, Sweden). NIOX1 mea-
sures eNO in exhaled air according to American Thoracic
Society guidelines [20]. This chemiluminescence gas analyser is
sensitive to eNO at concentrations ranging from 1.5–200 ppb
and demonstrates a deviation from the mean value of
+2.5 ppb at eNO <50 ppb or +5% of the measured value at
>50 ppb.
Sputum collection and processing
Subjects first inhaled 200 μg salbutamol and consecu-
tively nebulised hypertonic saline at concentrations of
3%, 4% and 5% at intervals of every seven minutes. Dur-
ing this procedure, it was important to flush and clean
the nose for disposal of the lower portion of squamous
epithelium cells in the samples. Sputum was processed
within one hour of collection. The selected sputum
plugs were separated from saliva as much as possible,
processed into a weighed Eppendorf tube, and processed
with 4x weight/volume of 0.1% dithiothreitol (DTT).
Afterward, 2 x weight/volume of phosphate-buffered sa-
line (PBS) was added. Samples were filtered through 48-
μm mesh and were centrifuged for 10 minutes at 790 x g.
Cells were counted in a haematocytometer, and 60,000 cells per
slide were prepared by cytocentrifugation (Cytospin 2; Shandon,.
Runcorn, UK). To ensure the quality of the induced sputum
one criteria is to keep levels of squamous epithelial cells low.
Samples were considered satisfactory if there were less than 10%
squamous epithelial cells. At least 400 inflammatory cells were
counted for each specimen. Cells were expressed as percentages
of the total cell count. The qRT-PCR cells were in RNAcell pro-
tect buffer (Qiagen (Valencia, CA).
Quantitative Real-Time PCR (qRT-PCR)
Total RNA from sputum cells was extracted using the
innuPrep RNA Mini Kit (Analytic Jena, Jena, Germany),
according to the manufacturer’s instructions. In this
assay, 5 μL of RNA was diluted 1:5 with RNase-free
water, and the absorbance was measured to determine
the amount of RNA. Before reverse transcription, a
DNase treatment was performed using the DNase I kit
(Qiagen, Hilden, Germany).
Reverse transcription of mRNA was performed in ac-
cordance with the manufacturer’s instructions (BioRad,
Hercules, CA, USA). Briefly, probes were supplemented
with 9 μL of a master mix of 1 μL iScript Reverse Trans-
ciptase (BioRad, Hercules, CA, USA), a random hexamer
and oligo dT mix, 4 μL 10x iScript RT buffer and 4 μL
nuclease-free water. These probes were incubated in a
thermocycler at 25°C for an initial incubation step for 5
Min, followed by another step at 42°C for 30 Min and
concluding at 85°C for 5 min.
Transcripts were quantified using two-step RT-PCR
with Eppendorf Mastercycler Realplex S detection sys-
tem (Eppendorf, Hamburg-Eppendorf, Germany) in
Greiner 25 μL 96-well reaction plates (Greiner, Germany).
The housekeeping gene glyceraldehyde-3-phosphate-dehydro-
genase (GAPDH) was used as control in each plate. Primers
for IL-5, IL-8, IFN-γ, and FoxP3 were designed by Qiagen (spe-
cific QuantiTect Primer Assays). PCR reactions were per-
formed according to the manufacturer’si n s t r u c t i o n si naf i n a l
volume of 25 μl using QuantiTect SYBR Green Master Mix
(Qiagen). Fluorescent product was detected at the last step of
each cycle. A melting curve analysis was carried out immedi-
ately after amplification in accordance with the manufacturer’s
instructions. Data expression and statistical analysis of genes
involved in immune cells and inflammation markers were
analysed.
Quantitative analysis was achieved based on the
threshold CT value for each well and calculated using
the Realplex S Database tool. The amount of mRNA ex-
pression was normalised with endogenous control
GAPDH. The relative quantification and calculation of
range of confidence were performed using the compara-
tive threshold cycle 2
-ΔΔCt method (relative gene expres-
sion), as described by Livak and Schmittgen [21].
We have chosen to measure mRNA rather than pro-
tein levels because of the higher sensitivity of the qRT-
PCR method compared protein measurements. In
addition, there is no dilution effect using cells instead of
supernatants after DTT-treatment of the sputum.
Laboratory measurements
Serum was analyzed for specific antibodies against total
IgE, specific IgE against against Dermatophagoides pter-
onyssinus IgE (D. pter), and sputum supernatants were
measured for eosinophilic cationic protein (ECP) using a
two-sided chemiluminescent assay (Immulite DPC, Bad
Nauheim, Germany). Analysis was performed accord-
ing to the manufacturer’si n s t r u c t i o n s .At o t a lI g Eo f
<100 kU/L was estimated as normal and a specific
IgE of>0.70 kU/L was estimated as positive.
Statistical analysis
For statistical analysis, GraphPad Prism 5.01 (GraphPad
Software, Inc.) and Microsoft Excel were used. Pulmon-
ary function parameters, eNO, PD20FEV1 methacholine,
and cytokine expressions before and after the provoca-
tion period were expressed as arithmetic means and
standard deviations (SDs). Differences between visits
were analysed using Student’s paired t-test or Wilcoxon
signed rank test, depending on normality assumptions
and the homogeneity of variances. In the case of more
than 2 visits, a non-parametric Friedmann test was used.
A p-value of≤0.05 was considered to be significant.
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Screening visits
Twenty-seven subjects, aged 18 to 40 years, were
included. In advance, participants were screened for total
IgE and specific IgE against house dust mite (D. pter.).
Both mean values were elevated and the RAST class was
at least II. All subjects underwent the incremental chal-
lenge with mite allergen. Baseline FVC values were
107.7% of predicted±10.4, and baseline FEV1 values
were 103.4% of predicted±12.7 (Table 1). Mean
PD15FEV1 dose in the incremental challenge was 62.4
SBU±53.6 (standardised biological units). The calcu-
lated PD15FEV1 was re-challenged in the first single-step
challenge, and as expected [2], 18 of 27 subjects had a
drop of maximum 15%±5 in FEV1. After adjustment of
the dose, eight of the remaining nine subjects had a fall
of 15%±5 in FEV1 with a second single-step challenge.
One subject was re-adjusted and successfully challenged
a third time. The mean drop in FEV1 in the successful
challenges was 15.6%±4.3.
Provocation period
After the screening visits all 27 subjects were gradually
randomised into the intervention. Then the subjects
were included in the provocations seven to 14 months
(median eight months) after the screening visit. Of the
subjects, seven did not fulfil the protocol; in single-step
challenges, two subjects had a drop of<10% FEV1; three
subjects had a drop of>50% FEV1 at visit 2; and in two
subjects the baseline FEV1 was below 75% at visit 3.
Two subjects had to stop the protocol, due to asthma
attacks and the need of prednisolone during the night
after visits 2 and 3, respectively. At least 18 subjects
were included per protocol.
Use of salbutamol and LAR
In the week before the provocation period, all subjects
had no need for salbutamol, and during the intervention
period (median eight months), only four subjects used
salbutamol for asthma symptoms. During the provoca-
tion period, the subjects received a mean of 3.5 puffs sal-
butamol (SD 5.4) (Figure 2). Fifteen of 27 subjects
developed a LAR after single-step challenges (Table 2).
With the exception of four patients, all participants
showed at least one day in pre-challenge baseline FEV1 a
drop ≥200 mL compared with the initial value at visit 1.
Changes in PFT, BHR and eNO
In all subjects the mean drop in FEV1 during the EAR
was 9.6%±9.9 at V1, 17.5%±14.6 at V2, 11.2%±10.5 at
V3, and 11.2%±15.9 at V4. The drop during the EAR
was not different between visits 2 to 4 (p=0.30)
(Figure 3a). Figure 3b indicates the 15 subjects that
developed LARs. The mean drop in FEV1 during the
EAR was 11.8%±10.4 at V1, 28.7%±15.3 at V2,
23.8%±11.2 at V3, and 27.4%±18.9 at V4 (V2-V4,
p=0.85).
In the 18 subjects who fulfilled the protocol the baseline
FEV1 dropped from 101.9%±15.6 at visit 1 to 96.7%±14.7
at visit 5 (p<0.001) (Table 2). BHR and eNO changes were
highly significant. In the MCT, the PD20FEV1 methacho-
line dropped from 1.30 mg±1.08 at visit 1 to 0.45 mg±
0.72 at visit 5 (p<0.001) (Figure 4). The eNO increased
consistently after every challenge from 29.4 ppb±17.2 to
114.5 ppb±53.9 (p<0.001) (Figure 5, Table 2).
Total cell count, eosinophils, ECP, and neutrophils in
induced sputum
Induced sputum in 17 of 18 subjects was obtained and
analysed at the beginning (V1) and at the end of the
provocation period (V5). The numbers of the total cell
count were equally distributed in samples before and
after bronchial allergen challenges (median 927
.10
3 and
628
.10
3, p=0.80) (Figure 6a). The total eosinophil count
significantly increased from median 5.28
.10
3 to 46.2
.10
3
(p<0.01) and the percentage of eosinophils from mean
0.9%±0.8 to 11.2%±8.5, respectively (p<0.001)
(Figure 6b,c). The levels of eosinophil cationic protein
(ECP) increased from median 61.2 ng/ml to 523.3 ng/ml
(p<0.01) (Figure 6d), whereas the ECP expressed as per
unit of eosinophils was unchanged (median 0.52 and
0.20 units, p=0.64) (Figure 6e). The percentage of neu-
trophils did not change (9.8%±6.1 and 7.1%±6.0,
p=0.15) (data not shown).
Cytokine and Forkhead box protein 3 (Foxp3) expressions
in sputum
The qRT-PCR showed a significant increase in IL-5
mRNA expression from 0.78±0.19 to 4281±2730
Figure 2 Salbutamol use during the provocation period (overall
mean 3.5 puffs). The mean day to day use did not change
significantly (p=0.59). The bronchodilator use directly after the
challenges is not included.
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expression of IFN-γ (from 7.78±4.87 to 0.59±0.28,
p=0.09). No differences were found in IL-8 mRNA ex-
pression (from 101.9±240.0 to 131.3±450.8, p=0.89).
In addition, transcription factor FoxP3 significantly
increased after an allergen challenge from 1.05±0.31 to
105.3±65.37, (p<0.05) (Figure 7a-d).
Long-term follow up
All subjects were asked to return at a median of
18 months after the previous visit for a long-term follow
up. As shown in Table 3, 22 of 27 subjects participated.
None of the participants showed a deterioration of the
lung function or changes in the total and specific IgE or
the BHR.
Discussion
Specific bronchial allergen provocation is an established
tool in asthma research for proof-of-concept studies of
new anti-inflammatory agents [16]. Repeated low-dose
provocations imitate the natural allergen exposure. The
standard high-dose allergen-inhalation challenge is usu-
ally performed to provoke the EAR and the LAR, and a
proportion of asthmatics experience airway inflamma-
tion characterised by the presence of activated eosino-
phils [1]. Both standard and low-dose allergen
provocations are safe when performed by experienced
investigators and do not lead to persistent worsening of
asthma or changes in airway function [16].
We aimed to induce airway inflammation and asthma
symptoms by repeated high-dose provocation to estab-
lish a model that demonstrates the potency of a new
agent to reduce severe asthma symptoms in small sam-
ple sizes. It is a matter of debate whether clinical studies
of spontaneous asthma exacerbations should continue to
be the gold standard for that end-point or if an agent
might be proven in asthma volunteers and in small sam-
ple sizes under clinical conditions. Nevertheless, there
are concerns about the feasibility and safety of this
approach.
Moreover, it cannot be taken for granted that the wor-
sening induced by four consecutive days of allergen chal-
lenge is relevant to the mechanisms in naturally
occurring exacerbations. However, for asthma patients
with severe allergies, it is impossible under certain con-
ditions to escape repeated allergen exposures (e.g., Cla-
dosporium allergy). These are patients who develop
severe exacerbations despite therapy with high doses of
inhaled corticosteroids and long-acting beta-agonists.
This study is the first to investigate the feasibility of
this approach and the immune response after repeated
high-dose bronchial allergen challenges with household
dust mites in stable asthmatics within one week. We
revealed a significant decrease of pulmonary function,
an increased use of rescue medication and the
Table 2 LAR, use of Salbutamol, FEV1 and eNO during provocation period
V1 V2 V3 V4 V5 p
LAR (all subjects, n=27) [n] 8 9 7 11
Use of salbutamol (n=27) [puffs, mean±SD] 0.85±1.6 0.74±1.5 0.74±1.2 1.18±2.0 0.59
Pre-challenge FEV1 (n=18) [absolute L, mean±SD] 4.03±0.93 3.86±0.88 3.79±0.99 3.83±0.92 3.83±0.90 <0.001
Pre-challenge FEV1 (n=18) [% pred, mean±SD] 101.9±15.6 97.4±13.3 95.5±17.6 97.1±16.1 96.7±14.7 <0.001
eNO (n=18) [ppb, mean±SD] 29.4±17.2 65.4±31.2 93.5±45.3 110.5±51.4 114.5±53.9 <0.0001
Figure 3 Maximal drop in FEV1 during the early asthmatic response after the single-step challenges. (a). All subjects (n=27), V0
represents the screening values. The mean drop in FEV1: V0, 15.6%±4.3; V1, 9.6%±9.9; V2, 17.5%±14.6; V3, 11.2%±10.5; V411, 2%±15.9. The
values were not different between visits 2 and 4 (p=0.30). (b). The 15 subjects that developed LARs. The mean drop in FEV1: V1, 11.8%±10.4; V2,
28.7%±15.3; V3, 23.8%±11.2; V4, 27.4%±18.9. The values were not different between visits 2 and 4 (p=0.85).
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induction of eosinophils and Th-2 cytokines.
It is important to determine whether the current
protocol, which clearly results in at least a short-term
progressive worsening of asthma, has a long-term im-
pact on the future health of the individual. We re-
investigated 22 of 27 subjects 18 months after the last
visit. None of the participants showed deterioration of
the lung function and, as shown by the specific IgE, no
increase of the sensitivity to dust mites was noted. The
BHR and the eNO, which were used as predictors of
asthma severity and bronchial inflammation, were
unchanged.
In the screening period, the subjects were re-
challenged with the calculated PD15FEV1 in single-step
challenges. In the first single-step challenge, 18 of 27
subjects exhibited a decrease in the FEV1 of a maximum
of 15%±5. A correlation between incremental and
single-step challenges has been confirmed in the litera-
ture [22,23]. The agreement of the decrease in FEV1 dur-
ing the EAR revealed an intra-class correlation of 0.55.
However, despite the good correlation, the authors de-
scribe relatively wide between-subject variabilities [22].
In the other study, 73% of the patients who demon-
strated a 20% drop in the FEV1 during the incremental
challenge produced a similar drop in the FEV1 in the
EAR during a single-dose inhalation. Among the entire
group, the repeatability according to Bland and Altman
was poor (95% limits of agreement of −29.5 - 22.5%)
[23]. The variability of the maximal decrease in FEV1
during the EAR, which is better expressed by the 95%
limit of agreement than by correlation coefficients [24],
was also shown in our previous [2] and present study.
Different bronchial provocation models show different
outcomes regarding asthma symptoms and medication
use. In repeated low-dose allergen provocations, night
time asthma symptoms and night time β2-agonist use
significantly increased during the challenging period,
and the PC20 methacholine levels were significantly
reduced [8]. In contrast, in another study using birch
and grass pollen provocations, no patient experienced
any significant early- or late-phase reactions [11]. Like-
wise, after inhalations of low doses of cat allergen, no
patient experienced any asthmatic symptoms [25]. In a
placebo controlled study with inhaled steroids, in 26
patients with mild asthma and mite allergy, repeated
inhalations of the PD5 allergen were performed for two
consecutive weeks. The β2-agonist use was significantly
elevated in the placebo group, whereas there were no
significant differences in the total daily symptom scores
or in the FEV1 within or between the groups. In the pla-
cebo group, the PC20 methacholine levels did not de-
crease significantly after 2 weeks of allergen exposure
[12]. In a similar protocol using the APS system, our
working group showed that not all participants needed
β2-agonists during the challenges with house dust mites
despite of induction of allergic airway inflammation. The
PD20 methacholine levels decreased in the placebo
group, but the difference failed to reach significance
[14]. In summary, in low-dose allergen challenges, sub-
jects usually do not develop asthma symptoms and the
elevated use of β2-agonists and day and night time
symptoms are rare.
In repeated high-dose provocations, Rosenthal et al.
[26] challenged patients who were allergic to ragweed on
four successive days with stepwise inhalations of the
antigen. A cumulative dose required for a 35% reduction
Figure 4 The PD20FEV1 methacholine on a logarithmic scale
before and after the bronchial allergen challenges. The
PD20FEV1 decreased significantly from1.30 mg±1.08 to
0.45 mg±0.72 (p<0.001).
Figure 5 Increase of exhaled NO 24 hours after the single-step
challenges. After each visit, the values increased stepwise. The data
points are connected by lines that indicate individual courses of
high, medium, and low responders.
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(PD35). In this study, only two patients had delayed,
self-limiting reactions. Grainge and Howarth [15] estab-
lished a model for repeated high-dose allergen chal-
lenges. They performed three provocations with the
PD15 mite allergen at 48-hour intervals. The mean daily
symptom score and the use of medication to relieve the
symptoms during the week of the challenges increased
significantly. With this design, the investigators did not
observe serious adverse events, such as significant wor-
sening of asthma symptoms requiring hospital admis-
sion, nor was there any requirement for the introduction
Figure 6 Sputum cells and ECP before and after the bronchial allergen challenges. (a). The total cell number was equally distributed in
both samples (p=0.80). (b and c). The total count and percentage of eosinophils increased significantly (p<0.001). (d and e). The ECP increased
significantly (p<0.01), whereas the cytokine levels were unchanged in relation to the eosinophil cell counts (p=0.64).
Table 3 Long-term follow-up
V0 18 months p
Subjects n=22
Male/Female 9/13
FVC [%pred, mean±SD] 107.7±10.4 108.5±10.6 0.60
FEV1 [%pred, mean±SD] 103.4±13.2 100.5±11.9 0.19
FEV1%FVC [%, mean±SD] 81.9±6.5 79.2±8.7 0.07
Total IgE [kU/L, mean±SD] 152.9±107.9 166.2±133.6 0.33
Spec. IgE D.pter. [kU/L, mean±SD] 28.7±27.1 26.8±22.6 0.90
PD20FEV1 metha [mg, mean±SD] 1.3±1.0 1.0±1.1 0.38
eNO [ppB, mean±SD] 26.1±14.0 31.8±21.4 0.25
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aggressive approach. Seven subjects developed progres-
sively more severe reactions, including two asthma
exacerbations requiring oral steroid treatment. Four con-
secutive provocations with the PD15 dose at a daily inter-
val led to an “overprovocation”, and such a protocol is
not suitable for routine use or in experimental asthma
research. However, high-dose provocations, e.g., the
protocol suggested by Grainge and Howarth, are models
that have been used in proof-of-concept studies to inves-
tigate the effect of asthma and antiallergic agents on
symptoms and medication use.
In keeping with Grainge and Howarth [15], we found
a significantly increased use of salbutamol and the devel-
opment of LAR. The evaluation of the LAR using peak-
flow meters might be disadvantageous because small
changes in airway obstruction might be missed. How-
ever, two previous studies [27,28] showed that peak-flow
measurements are a valuable tool to detect an LAR. The
cut-off of a 15% decrease in PEF represents a significant
LAR reaction, but values of less than 15% might be less
sensitive than FEV1 monitoring. Furthermore, salbuta-
mol was given after the allergen challenges. Short-acting
ß-agonists reverse the LAR when it is not too severe;
however, they do not prevent the LAR or any of the
associated inflammatory events [16]. The protocol of this
study is not suitable to reveal mild LAR, and the magni-
tude of the LAR might be biased. However, severe LARs
are detected by PEF measurements and not prevented
by ß-agonists.
Interestingly, with the exception of four subjects, all of
the participants had at least one day with a pre-
challenge baseline FEV1≤200 ml compared with the ini-
tial value, and the overall baseline FEV1 dropped signifi-
cantly. Thus, the changes of PFT, the medication use,
and the increase of BHR clearly demonstrate that the
high-dose provocation model is an excellent tool to in-
duce asthma worsening in stable step 1 asthmatics.
The finding that allergen exposure increased airway
hyperresponsiveness to histamine or methacholine was
first described in the classic publication by Cockcroft et al.
[29]. A numerous number of subsequent publications
confirmed the link between allergen-induced bronchial in-
flammation and BHR. Cartier et al. [30] were the first to
demonstrate that the magnitude and duration of the de-
crease in PC20 histamine correlated with the magnitude of
the LAR. As expected, we found a marked decrease in
PD20 methacholine after the provocation period.
Kharitonov et al. [31] first reported that allergen-
induced inflammation by single-allergen challenges
Figure 7 Cytokine expression in the sputum before and after bronchial allergen challenges. The values are related to the total cell
numbers. (a). A significant increase in IL-5 expression (p<0.01). (b). The IFN-γ expression did not significantly decline (p=0.09). (c). The IL-8
expression was unchanged (p=0.89). (d). A significant increase in Foxp3 expression (p<0.05).
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ing repeated low-dose allergen challenges, significant
increases in eNO occurred [12,14]. We recently investi-
gated the increase of eNO levels 24 hours after single-
step challenges. Two challenges with the same amount
of allergen were performed without worsening of asthma
symptoms [2]. The intra-class correlation between both
measurements showed substantial agreement (0.62,
p<0.001), whereas the limits of agreement revealed
intra-individual variations.
In the present study, we demonstrated that repeated
high-dose allergen challenges caused significant stepwise
increases in eNO, beginning with the first provocation. It is
somewhat surprising that an identical allergen dose, at least
on the group level, reproducibly provided identical 15%
drops in the FEV1, suggesting the development of tolerance.
The development of tolerance implies an effect on Th-1
cytokines or a suppression of Th-2 cytokines. Thunberg
et al. [32] investigated birch pollen-allergic patients and
healthy controls and evaluated the local and systemic regu-
latory mechanisms in the EAR to bronchial allergen provo-
cation. CD25+CD4+ Treg cells were not as effective in
their suppression of Th-2 responses, providing an explan-
ation for the inability of infiltrating Treg cells to suppress
Th-2 driven asthmatic responses to allergen provocation in
the lung. By contrast, in inhaled and segmental bronchial
challenges, IFN-γ levels did not differ between the asth-
matic patients and the controls, and they were not affected
24 hours after allergen provocation [32,33]. However, Th-1-
associated chemokines were present at 48 hours and may
recruit a subsequent wave of Th-1-type lymphocytes that
downregulate the on-going Th-2-type response [34]. In
contrast, we found a decreasing trend in IFN-γ expression
in repeated high-dose allergen challenges. Three repeated
high-dose allergen provocations at 48-h intervals produced
a similar decrease in the EAR and FEV1 in all challenges
(p=0.83), and there was no significant change in the base-
line pre-challenge FEV1 (p=0.53) [15]. It seems that, des-
pite the induction of allergic inflammation, GINA I°
asthmatics recover rather rapidly after bronchial challenges,
as suggested by the constant pre-challenge lung function
and the similar course of the EAR.
The induction of eosinophils by the allergen challenges
is an important mechanism for the understanding of the
allergic airway inflammation pathway and the link to
LAR. De Monchy et al. [35] performed bronchoalveolar
lavage (BAL) after allergen challenges in patients with
asthma and in control subjects. In the BAL fluid of the
patients, a significant eosinophilia was found, and the
authors suggested that eosinophils and their mediators
might be involved in the development of LAR after aller-
gen inhalation. In two consecutive challenges with the
same dose of allergen, the intra-class correlation coeffi-
cient for sputum eosinophils was 0.60 at 7 hours and
0.53 at 24 hours after the challenge [1]. The authors
concluded that allergen inhalation challenges with mea-
surements of sputum eosinophils are a noninvasive and
reliable method to evaluate the anti-inflammatory effects
of asthma therapies. In low-dose allergen challenges, a
significant increase in the number of sputum eosinophils
and/or ECP level was found [8,12,14,25]. The induction
of eosinophils and ECP was more likely to occur in aller-
gen challenges that provoked asthma symptoms or an
increased use of salbutamol. However, it is surprising
that the percentage of change in the eosinophil level in
sputum at visit 5 was lower than that published by other
groups 24 hours after a single high-dose allergen chal-
lenge [1,36]. Our results compare with similar changes
in sputum eosinophils in low-dose allergen challenges
[12,14]. In contrast, Sulakvelidze et al. [8] reported an
increase in eosinophils of up to 21.2% in low-dose chal-
lenges. In high-dose allergen challenges, a percentage in-
crease in eosinophils from 3.8% to 18.2% and from 7.2%
to 31.8% was found, respectively [1,36]. In the former
studies, the participants were mild asthmatics [12,14],
whereas in the latter ones, the participants were
screened to have an EAR and LAR [1,8] or 9 of 12 sub-
jects had a definite late response [36]. The precondition
of an LAR might have influenced the response after the
allergen challenges, resulting in higher eosinophil levels.
We demonstrated that high-dose allergen provocation
causes a significant elevation of eosinophils as well as a
significant increase in the ECP levels. Therefore, proin-
flammatory effects might depend on the concentration
and/or dosage of the inhaled allergen.
IL-5 is produced by Th-2 cells and is a key mediator of
eosinophil activation. In low-dose allergen challenges, a
significant increase in IL-5 was detected at day 5 [8], and a
significant increase of the IL-5/IFN-γ ratio was only
detected at day 19 [12], suggesting an increase in IL-5
and/or a drop in IFN-γ. In segmental allergen challenges
in asthmatics, the IL-5 levels in BAL were low at baseline
and increased after the challenge [33,34]. We demon-
strated a significant increase in the IL-5 levels and an al-
most significant decrease in the IFN-γ levels after the
provocation period. These results indicate that the aller-
gen challenges induced IL-5 in either sputum or BAL.
The effect of the bronchial challenges on the balance of
Th-1 and Th-2 is supported by our findings of Foxp3 upre-
gulation. The appearance of Foxp3 suggests the involve-
ment of CD25+CD4+ Treg cells. Foxp3 is predominantly
expressed in the CD25+CD4+ Treg population, and Foxp3
expression in naïve Tcells can convert these cells to a regu-
latory T cell phenotype that is functionally similar to natur-
ally occurring CD25+CD4+ Treg cells [37].
Most studies on immune regulation are performed on
cells obtained from peripheral blood, which may not re-
flect the situation in the target organ. Thus, studies on
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sential [32]. Hartl et al. [38] reported that CD4
+CD25
hi
T cells were decreased in the BAL of asthmatic children
compared with values in children with cough or control
subjects, and the BAL CD4
+CD25
hi T-cells from asth-
matic subjects failed to suppress pulmonary Th-2
responses. The numbers of CD69+ and Foxp3+ lympho-
cytes were higher in the BAL after, compared with be-
fore, allergen provocation in asthmatic patients [32].
Foxp3 CD4
+CD25
+ Treg cells contribute to the con-
trol of allergen-specific immune responses in several
major ways, e.g., the regulation of effector Th-1 and Th-
2 cells [39]. Orihara et al. [40] showed that the
Foxp3CD4 ratios correlated inversely at statistically sig-
nificant levels with the serum total IgE level, eosinophil
ratio, and serum IFN-γ level. Foxp3 as a marker for
human Treg cells has some limitations, as T-effector
cells transiently express Foxp3 after activation. However,
CD4+CD25 cells intracellularly stained for Foxp3 dis-
played significantly higher fluorescence intensity after,
compared with before, allergen provocation. This finding
indicates that the observed increase in infiltrating Foxp3
+ cells corresponds to an increase in the number of
functional Treg cells [32].
To the best of our knowledge, we are the first group
to have shown that Foxp3 is expressed in sputum cells
after bronchial allergen challenges, suggesting a modu-
lating role of Treg cells after allergen exposure.
Repeated high-dose bronchial allergen challenges did
not influence neutrophilic inflammation. In our study, as
well as in the study by de Kluijver et al. [12], the number
of neutrophils and the levels of IL-8 or neutrophil elas-
tase in sputa were not affected by high- or low-dose al-
lergen challenges, respectively.
Conclusions
High-dose allergen challenges caused significant asthma
worsening, increased salbutamol use, and induced BHR.
Moreover, a marked Th-2 mediated inflammation in-
volving eosinophils and high NO was demonstrated. The
high-dose challenge model is suitable only in an attenu-
ated form in disease volunteers in proof-of-concept
studies and in clinical settings to reduce the risk of se-
vere asthma exacerbations.
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